Indication
Cervical cancer
4 clinical trials
7 products
2 drugs
Clinical trial
A Randomized, Double-blind, Controlled, Parallel-cohort Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based ChemotherapyStatus: Completed, Estimated PCD: 2023-11-20
Product
PlaceboProduct
SintilimabProduct
IBI310Clinical trial
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERVStatus: Terminated, Estimated PCD: 2019-07-31
Product
ADXS11-001Clinical trial
A Randomized Phase III Trial of Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab Versus Platinum Chemotherapy Plus Paclitaxel and Bevacizumab in Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the CervixStatus: Active (not recruiting), Estimated PCD: 2024-11-01
Drug
AtezolizumabProduct
Cisplatin/CarboplatinDrug
TiragolumabClinical trial
A Phase 1b/2 Study With the Agonistic TRAIL-R1 Antibody, Mapatumumab, in Combination With Cisplatin and Radiotherapy as a First Line Therapy in Patients With Advanced Cervical Cancer.Status: Completed, Estimated PCD: 2014-03-01
Product
mapatumumabProduct
cisplatin